Akamai Technologies (AKAM) PT Lowered to $60 at Oppenheimer Following 2Q Release
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Akamai Technologies (AKAM) PT Lowered to $54 at RBC Capital; Reiterates Sector Perform
July 26, 2017 8:04 AM EDTRBC Capital lowered its price target on Akamai Technologies (NASDAQ: AKAM) to $54.00 (from $58.00) while maintaining a Sector Perform rating following the company's 2Q. Revenue of $609MM came in above the Street's estimates of $605, with upside coming from the Media Delivery segment.
Q3 Revenue and... More
Akamai Technologies (AKAM) PT Lowered to $48 at Morgan Stanley
July 26, 2017 7:57 AM EDTMorgan Stanley lowered its price target on Akamai Technologies (NASDAQ: AKAM) to $48.00 (from $52.00) while maintaining a Underweight rating.
... MoreAkamai Technologies (AKAM): Low Conviction In Estimates - Cowen
July 26, 2017 7:34 AM EDTCowen analyst, Colby Synesael, reiterated his Market Perform rating on shares of Akamai Technologies (NASDAQ: AKAM) and cut his price target to $60 after the company reported good 2Q17 results but provided 3Q17 guidance below previous Street expectations.
The analyst stated... More
Akamai Technologies (AKAM): Cutting PT On Increasing Competition - Stifel
July 26, 2017 5:51 AM EDTStifel analyst, Matthew Heinz, reiterated his Hold rating on shares of Akamai Technologies (NASDAQ: AKAM) and cut his price target to $56 after the incremental news on AKAM's 2Q conference call largely revolved around the recent slippage in low-end CDN traffic moving across its... More
After-Hours Movers 07/25: (TTPH) (IRBT) (X) (AMD) Higher; (USNA) (CHGG) (AKAM) Lower (more...)
July 25, 2017 6:20 PM EDTToday's After-Hours Movers
Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) 23.2% HIGHER; announced positive top-line results from IGNITE4, the Company's phase 3 clinical trial evaluating the efficacy and safety of twice-daily intravenous (IV) eravacycline compared to meropenem for the treatment of patients with complicated intra-abdominal infections (cIAI). The results of IGNITE4, which enrolled 500 patients, demonstrated statistical non-inferiority of eravacycline to meropenem for the primary efficacy endpoint of clinical response at the test-of-cure (TOC) visit.
iRobot Corp. (NASDAQ: IRBT) 23.2% HIGHER; reported Q2 EPS of $0.27,... More
Akamai Technologies (AKAM) Tops Q2 EPS by 2c, Beats on Revenues
July 25, 2017 4:02 PM EDTAkamai Technologies (NASDAQ: AKAM) reported Q2 EPS of $0.62, $0.02 better than the analyst estimate of $0.60. Revenue for the quarter came in at $609 million versus the consensus estimate of $604.54 million.
Revenue of $609 million, up 6% year-over-year and 7% when adjusted for foreign exchange*Revenue excluding Internet... MoreAkamai (AKAM) July weekly IV increases to 98 into Q2
July 24, 2017 3:00 PM EDTAkamai Technologies (NASDAQ: AKAM) July weekly call option implied volatility is at 98, August is at 45; compared to its 52-week range of 19 to 51 into the expected release of Q2 results on July 25.
... More